Skip to main content
SpringerLink
Log in

Uricase and other novel agents for the management of patients with treatment-failure gout

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medications fail to achieve this benchmark, resulting in ongoing signs and symptoms characteristic of treatment-failure gout. Potential therapies now in clinical development show promise for treating this refractory patient population. In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Becker MA, Jolly M: Clinical gout and pathogenesis of hyperuricemia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15, vol. 2. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott Williams and Wilkins; 2005:2303–2340.

    Google Scholar 

  2. Sarawate CA, Patel PA, Schumacher HR, et al.: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61–65.

    Article  PubMed  Google Scholar 

  3. Fang W, Zeng X, Li M, et al.: The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 2006, 33:2041–2049.

    PubMed  Google Scholar 

  4. Lawry GV 2nd, Fan PT, Bluestone R: Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine (Baltimore) 1988, 67:335–343.

    Article  Google Scholar 

  5. Mikuls TR, Curtis JR, Allison JJ, et al.: Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006, 33:562–566.

    PubMed  Google Scholar 

  6. Mikuls TR, Farrar JT, Bilker WB, et al.: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005, 44:1038–1042.

    Article  CAS  Google Scholar 

  7. Mikuls TR, MacLean CH, Olivieri J, et al.: Quality of care indicators for gout management. Arthritis Rheum 2004, 50:937–943.

    Article  PubMed  Google Scholar 

  8. Mikuls TR, Saag KG: Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care? Curr Rheumatol Rep 2005, 7:242–249.

    Article  PubMed  Google Scholar 

  9. Neogi T, Hunter DJ, Chaisson CE, et al.: Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006, 33:104–109.

    PubMed  Google Scholar 

  10. Pal B, Foxall M, Dysart T, et al.: How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21–25.

    Article  PubMed  CAS  Google Scholar 

  11. Sarawate CA, Brewer KK, Yang W, et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925–934.

    Article  PubMed  Google Scholar 

  12. Smith P, Karlson N, Nair BR: Quality use of allopurinol in the elderly. J Qual Clin Pract 2000, 20:42–43.

    Article  PubMed  CAS  Google Scholar 

  13. Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450–2461.

    Article  PubMed  CAS  Google Scholar 

  14. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47–56.

    Article  PubMed  CAS  Google Scholar 

  15. Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646–1650.

    PubMed  CAS  Google Scholar 

  16. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60:981–983.

    Article  PubMed  CAS  Google Scholar 

  17. Hahn PC, Edwards NL: Management of hyperuricemia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15, vol. 2. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott Williams and Wilkins; 2005:2341–2355.

    Google Scholar 

  18. de Klerk E, van der Heijde D, Landewe R, et al.: Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003, 30:44–54.

    PubMed  Google Scholar 

  19. Riedel AA, Nelson M, Joseph-Ridge N, et al.: Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004, 31:1575–1581.

    PubMed  Google Scholar 

  20. Sundy JS, Becker MA, Schumacher HR, et al.: Multicenter longitudinal study of disease characteristics in patients with treatment failure gout. Ann Rheum Dis 2006, 65:272.

    Article  Google Scholar 

  21. Sundy JS, Schumacher HR, Becker MA, et al.: Quality of life in patients with treatment failure gout. Ann Rheum Dis 2006, 65:271.

    Article  CAS  Google Scholar 

  22. Becker MA, Kisicki J, Khosravan R, et al.: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004, 23:1111–1116.

    Article  PubMed  CAS  Google Scholar 

  23. Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916–923.

    Article  PubMed  CAS  Google Scholar 

  24. Hoshide S, Takahashi Y, Ishikawa T, et al.: PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004, 23:1117–1118.

    Article  PubMed  CAS  Google Scholar 

  25. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858–6862.

    Article  PubMed  CAS  Google Scholar 

  26. Wu X, Wakamiya M, Vaishnav S, et al.: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994, 91:742–746.

    Article  PubMed  CAS  Google Scholar 

  27. Kelly SJ, Delnomdedieu M, Oliverio MI, et al.: Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001–1009.

    PubMed  CAS  Google Scholar 

  28. Moolenburgh JD, Reinders MK, Jansen TL: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006, 25:749–752.

    Article  PubMed  CAS  Google Scholar 

  29. Richette P, Bardin T: Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006, 2:338–342; quiz 343.

    Article  PubMed  CAS  Google Scholar 

  30. Rozenberg S, Roche B, Dorent R, et al.: Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995, 62:392–394.

    PubMed  CAS  Google Scholar 

  31. Vogt B: Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005, 20:431–433.

    Article  PubMed  CAS  Google Scholar 

  32. Davis S, Park YK, Abuchowski A, Davis FF: Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet 1981, 2:281–283.

    Article  PubMed  CAS  Google Scholar 

  33. Chua CC, Greenberg ML, Viau AT, et al.: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988, 109:114–117.

    PubMed  CAS  Google Scholar 

  34. Ganson NJ, Kelly SJ, Scarlett E, et al.: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12.

    Article  PubMed  CAS  Google Scholar 

  35. Sundy JS, Ganson NJ, Kelly SJ, et al.: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021–1028.

    Article  PubMed  CAS  Google Scholar 

  36. Sundy JS, Becker MA, Baraf HS, et al.: A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout [abstract]. Arthritis Rheum 2005, 52:S679.

    Article  Google Scholar 

  37. Baraf HS, Kim S, Matsumoto AK, Maroli AN: Resolution of tophi with intravenous PEG-uricase in refractory gout [abstract]. Arthritis Rheum 2005, 52:S105.

    Article  CAS  Google Scholar 

  38. Perez-Ruiz F, Calabozo M, Pijoan JI, et al.: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356–360.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University Medical Center, Box 3278 DUMC, 014 Baker House, Durham, NC, 27710, USA

    John S. Sundy MD, PhD

Authors
  1. John S. Sundy MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael S. Hershfield MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John S. Sundy MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sundy, J.S., Hershfield, M.S. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 9, 258–264 (2007). https://doi.org/10.1007/s11926-007-0041-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0041-y

Keywords

Search

Navigation